An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome

Journal of Controlled Release

Volumn 221, Issue , 2016, Pages 1-8

  Wibroe, Peter P ^a   Ahmadvand, Davoud ^b   Oghabian, Mohammad Ali ^c   Yaghmur, Anan ^a   Moghimi, S Moein ^a,d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Complement system; Cryo TEM; Nanomedicine; Nanosimilars; Non biological complex drugs

Indexed keywords

ASPECT RATIO; CHEMICAL ACTIVATION; DRUG PRODUCTS; HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY; LIGHT SCATTERING; LIPOSOMES; MEDICAL NANOTECHNOLOGY; TRANSMISSION ELECTRON MICROSCOPY;

COMPLEMENT ACTIVATIONS; COMPLEMENT SYSTEMS; CRYO-TEM; CRYOGENIC TRANSMISSION ELECTRON MICROSCOPY; NANOPARTICLE TRACKING ANALYSIS; NANOSIMILARS; NON-BIOLOGICAL COMPLEX DRUGS; US FOOD AND DRUG ADMINISTRATION;

PRODUCT DESIGN;

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; DOXORUBICIN; LIPOSOME; ANTINEOPLASTIC ANTIBIOTIC; MACROGOL DERIVATIVE;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTRAST ENHANCEMENT; CONTROLLED STUDY; HUMAN; IMAGE PROCESSING; NANOPHARMACEUTICS; PARTICLE SIZE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; X RAY CRYSTALLOGRAPHY; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; ULTRASTRUCTURE;

ANTIBIOTICS, ANTINEOPLASTIC; COMPLEMENT ACTIVATION; DOXORUBICIN; HUMANS; LIPOSOMES; PARTICLE SIZE; POLYETHYLENE GLYCOLS;

EID: 84948464298     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.11.021     Document Type: Article

References (41)

1. Y. Barenholz Doxil® - the first FDA-approved nano-drug: lessons learned J. Control. Release 160 2012 117 134
2. S. Tinkle, S.E. McNeil, S. Mühlebach, R. Bawa, G. Borchard, Y. Barenholz, L. Tamarkin, and N. Desai Nanomedicines: addressing the scientific and regulatory gap Ann. N.Y. Acad. Sci. 1313 2014 35 56
3. S.M. Moghimi, and Z.S. Farhangrazi Defining and characterizing nonbiological complex drugs (NBCDs) - is size enough? The case for liposomal doxorubicin generics ('liposomal nanosimilars') for injection GaBI J. 3 2014 56 57
4. S. Gaspani, and B. Milani Access to liposomal generic formulations: beyond AmBisome and Doxil/Caelyx GaBI J. 2 2013 60 62
5. S.M. Moghimi, D. Peer, and R. Langer Reshaping the future of nanopharmaceuticals: ad iudicium ACS Nano 5 2011 8454 8458
6. M.L. Chen, V. Shah, R. Patnaik, W. Adams, A. Hussain, D. Conner, M. Mehta, H. Malinowski, J. Lazor, S.M. Huang, D. Hare, L. Lesko, D. Sporn, and R. Williams Bioavailability and bioequivalence: an FDA regulatory overview Pharm. Res. 18 2001 1645 1650
7. S.E. McNeil Characterization of Nanoparticles Intended for Drug Delivery 2011 Humana Press/Springer New York
8. EMA guideline on biosimilar medicinal products http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/10/WC500176768.pdf 2014 (accessed October 2015)
9. D.J.A. Crommelin, V.P. Shah, I. Klebovich, S.E. McNeil, V. Weinstein, B. Fluthmann, S. Muhlebach, and J.S.B. de Vlieger The similarity question for biologicals and non-biological complex drugs Eur. J. Pharm. Sci. 76 2015 10 17
10. H. Schellekens, S. Stegemann, V. Weinstein, J.S.B. de Vlieger, B. Fluhmann, S. Muhlebach, R. Gaspar, V.P. Shah, and D.J.A. Crommelin How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider AAPS J. 16 2014 15 21
11. S.M. Moghimi, A.C. Hunter, and J.C. Murray Nanomedicine: current status and future prospects FASEB J. 19 2005 311 330
12. S.M. Moghimi, A.C. Hunter, and T.L. Andresen Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective Annu. Rev. Pharmacol. Toxicol. 52 2012 481 503
13. I. Hamad, and S.M. Moghimi Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug Expert Opin. Drug Deliv. 5 2008 205 219
14. R.I. MacCuspie, K. Rogers, M. Patra, Z.Y. Suo, A.J. Allen, M.N. Martin, and V.A. Hackley Challenges for physical characterization of silver nanoparticles under pristine and environmentally relevant conditions J. Environ. Monit. 13 2011 1212 1226
15. M.A. Hamburg FDA's approach to regulation of products of nanotechnology Science 336 2012 299 300
16. S.M. Moghimi, A.J. Andersen, D. Ahmadvand, P.P. Wibroe, T.L. Andresen, and A.C. Hunter Material properties in complement activation Adv. Drug Deliv. Rev. 63 2011 1000 1007
17. S.M. Moghimi, P.P. Wibroe, S.Y. Helvig, Z.S. Farhangrazi, and A.C. Hunter Genomic perspectives in inter-individual adverse responses following nanomedicine administration: the way forward Adv. Drug Deliv. Rev. 64 2012 1385 1393
18. J. Szebeni, F. Muggia, A. Gabizon, and Y. Barenholz Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention Adv. Drug Deliv. Rev. 63 2011 1020 1030
19. A. Chanan-Khan, J. Szebeni, S. Savay, L. Liebes, N.M. Rafique, C.R. Alving, and F.M. Muggia Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions Ann. Oncol. 14 2003 1430 1437
20. S.M. Moghimi, and I. Hamad Liposome-mediated triggering of complement cascade J. Liposome Res. 18 2008 195 209
21. G. Milosevits, Z. Rozsnyay, G.T. Kozma, J. Milosevits, G. Tomory, H. Robotka, L. Rosivall, and J. Szebeni Flow cytometric analysis of supravesicular structures in doxorubicin-containing pegylated liposomes Chem. Phys. Lipid. 165 2012 482 487
22. S. Mitragotri, and J. Lahann Physical approaches to biomaterial design Nat. Mater. 8 2009 15 23
23. J.A. Champion, Y.K. Katare, and S. Mitragotri Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers J. Control. Release 121 2007 3 9
24. Y. Geng, P. Dalhaimer, S.S. Cai, R. Tsai, M. Tewari, T. Minko, and D.E. Discher Shape effects of filaments versus spherical particles in flow and drug delivery Nat. Nanotechnol. 2 2007 249 255
25. J.A. Champion, and S. Mitragotri Role of target geometry in phagocytosis Proc. Natl. Acad. Sci. U. S. A. 103 2006 4930 4934
26. D.A. Christian, S.S. Cai, O.B. Garbuzenko, T. Harada, A.L. Zajac, T. Minko, and D.E. Discher Flexible filaments for in vivo imaging and delivery: persistent circulation of filomicelles opens the dosage window for sustained tumor shrinkage Mol. Pharm. 6 2009 1343 1352
27. Y. Schilt, T. Berman, X. Wei, Y. Barenholz, and U. Raviv Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs Biochim. Biophys. Acta-Gen. Subj. 1860 2016 108 119
28. Non-binding recommendations from FDA for liposomal Doxorubicin hydrochloride evaluation http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorInformation/Guidances/UCM199635.pdf 2014 (accessed October 2015)
29. A. Soundararajan, A. Bao, W.T. Phillips, R. Perez, and B.A. Goins [Re-186] Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model Nucl. Med. Biol. 36 2009 515 524
30. M. Wright Nanoparticle tracking analysis for the multiparameter characterization and counting of nanoparticle suspensions M. Soloviev, Nanoparticles in Biology and Medicine 2012 Humana Press 511 524
31. P. Van der Meeren, M. Kasinos, and H. Saveyn Relevance of two-dimensional Brownian motion dynamics in applying nanoparticle tracking analysis M. Soloviev, Nanoparticles in Biology and Medicine 2012 Humana Press 525 534
32. S.M. Moghimi, I. Hamad, T.L. Andresen, K. Jorgensen, and J. Szebeni Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production FASEB J. 20 2006 2591 2593
33. A.J. Andersen, J.T. Robinson, H.J. Dai, A.C. Hunter, T.L. Andresen, and S.M. Moghimi Single-walled carbon nanotube surface control of complement recognition and activation ACS Nano 7 2013 1108 1119
34. N.K. Banda, G. Mehta, Y. Chao, G.K. Wang, S. Inturi, L. Fossati-Jimack, M. Botto, L.P. Wu, S.M. Moghimi, and D. Simberg Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum Part. Fibre Toxicol. 11 2014 64 10.1186/s12989-014-0064-2
35. J. Kuntsche, J.C. Horst, and H. Bunjes Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems Int. J. Pharm. 417 2011 120 137
36. D.D. Lasic, P.M. Frederik, M.C.A. Stuart, Y. Barenholz, and T.J. Mcintosh Gelation of liposome interior - a novel method for drug encapsulation FEBS Lett. 312 1992 255 258
37. D.D. Lasic, B. Ceh, M.C.A. Stuart, L. Guo, P.M. Frederik, and Y. Barenholz Transmembrane gradient driven phase-transitions within vesicles - lessons for drug-delivery Biochim. Biophys. Acta-Biomembr. 1239 1995 145 156
38. X.G. Li, D.J. Hirsh, D. Cabral-Lilly, A. Zirkel, S.M. Gruner, A.S. Janoff, and W.R. Perkins Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient Biochim. Biophys. Acta-Biomembr. 1415 1998 23 40
39. M. Almgren, K. Edwards, and G. Karlsson Cryo transmission electron microscopy of liposomes and related structures Colloid. Surf. Physicochem. Eng. Aspects 174 2000 3 21
40. J. Szebeni, L. Baranyi, S. Savay, H.U. Lutz, E. Jelezarova, R. Bunger, and C.R. Alving The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (DOXIL®) J. Liposome Res. 10 2000 467 481
41. D. Lorusso, A. Di Stefano, V. Carone, A. Fagotti, S. Pisconti, and G. Scambia Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome) Ann. Oncol. 18 2007 1159 1164